Delisting from the Australian Securities Exchange (ASX)
On 11 October 2023, Kazia Therapeutics announced its intention to delist from the Australian Securities Exchange (ASX).
Following careful consideration, the Kazia Board has ultimately determined that the costs, administrative burden and commercial disadvantages of remaining listed on ASX outweigh any benefits of a continued ASX listing. Following the Delisting, the Company will maintain its listing on the NASDAQ and the fully paid ordinary shares in the Company (Shares) will no longer be quoted on the ASX.
Interview with Kazia CEO Dr John Friend regarding the Company’s intention to delist from the ASX
Resources for shareholders
An announcement setting out the background to the delisting application is listed below. This Announcement provides additional information on the rationale for the decision to de-list from the ASX. Also listed below is a letter to shareholders that provides further information about the delisting process, including the options available to shareholders and certain implications which may arise because of the delisting.
Next steps for shareholders
As a holder of Shares, you have the following options in respect of the Delisting, which you should carefully consider before deciding what to do with your Shares. If you do nothing, then Option 3 will apply by default.
OPTION 1: Sell your Shares on ASX on or before the Suspension Date
OPTION 2: Convert your Shares to ADSs
OPTION 3: Take no action by the Suspension Date
In order to read more about your options, please review the “Letter to Shareholders” available via the link below. A copy of the ADSs Conversion form is also listed below, which is to be completed by shareholders for the conversion of their ordinary shares into ADSs under ADS Conversion Facility.
Who can I contact for more information?
If you have a question in relation to the Delisting or any information set out in this letter please contact your tax advisor or Anna Sandham, Corporate Secretary at cosec@companymatters.com.au.
If you would like to subscribe to receive email alerts for Company news, including SEC announcements and media releases, please complete the form here.
